Background: We have recently reported a BMI-SDS increase in girls with Turner syndrome (TS) treated with growth hormone (GH) (1).
Objective and hypothesis: We hypothesise that puberty induction in TS is associated with weight gain.
Method: We analysed the weight changes (BMI-SDS) of 888 girls with TS in the Pfizer International Growth Database (KIGS). Overweight was defined by a BMI >90th percentile and obesity by a BMI >97th percentile. For univariate statistical comparisons, Wilcoxon rank sum test was used. For proportions, χ2 or Fisher Exact test was used for comparisons.
Results: Puberty was induced in 618 (70%) girls. The changes of weight status over time are shown in the Table. BMI-SDS did not change between onset of GH treatment and 1yr later, but increased afterwards (+0.2 until onset of puberty, P<0.05;+0.2 between onset of puberty and 2 years later, P<0.05).
Girls with spontaneous (S) and induced (I) puberty showed similar BMI-SDS changes (increase until start of puberty (S:+0.2;I:+0.2,P=0.61)) and in first 2 years of puberty (S:+0.1;I:+0.2, P=0.11)). BMI-SDS changes did not differ between early (E:<12 years, n=89) and late (L:>12 years; n=529) induced puberty (increase until onset of puberty (E:+0.2,L:+0.1, P=0.57) and in first 2 years of puberty (E:+0.2;L:+0.2, P=0.80)).
|Variable||Baseline (GH start)||1 year on GH||Puberty onset||Puberty at 2 years|
|Age (years)||9.1 (4.912.7)||10.1 (5.913.7)||13.0 (11.015.0)||15.0 (13.017.0)|
|BMI-SDS||0.1 (−1.21.6)||0.1 (−1.11.4)||0.4 (−0.91.8)||0.6 (−0.72.0)|
|Data as percentage or median (10/90 percentile).|
Conclusion: Nearly half of BMI-SDS increase was recorded before puberty onset and weight changes did not differ between girls with induced and spontaneous puberty. These findings do not support the hypothesis that administered estrogens had a significant impact on weight gain in TS girls.
Conflict of interest: Anders Lindberg, Jose Cara and Cecilia Camacho are employees of Pfizer Inc. Thomas Reinehr and Dionisis Chrysis act as members of KIGS Steering Committee.
Funding information: This work was funded by Pfizer Inc. New York USA.
01 - 03 Oct 2015
European Society for Paediatric Endocrinology